Z Gu1, K Hu1, Y Liang1, F Zhang1, A Tong2, X Hou3. 1. Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Dongdansantiao No. 5, Dongcheng District, Beijing, China. 2. Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. 3. Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Dongdansantiao No. 5, Dongcheng District, Beijing, China. hxr_pumch@163.com.
Abstract
PURPOSE: The purpose of this study was to review outcomes of patients with advanced/metastatic pheochromocytoma/paraganglioma (PPGL) treated at our institution with Intensity-modulated radiotherapy (IMRT), describe the treatment outcomes, and determine predictors. METHODS: A retrospective study on patients with advanced/metastatic PPGL who received IMRT at Peking Union Medical College Hospital between 2014 and 2019. A total of 14 patients with 17 lesions were included in this study. Ultra-hypofractionated radiation therapy was used for 7 lesions in 5 patients, while hypofractionated radiation therapy was used for 8 lesions in 7 patients. 2 patients got conventional fractionated radiotherapy. Patients who received external beam radiation therapy were given a median total radiation dose of 74.4/130 Gy (BED10/3) in a median of 13 fractions. RESULTS: OS at 2 years was 78% for all patients. For lesions evaluated by RECIST response, at least stable disease of the target lesion was achieved in 94% and distant progression in 28.5%, with an average time to progression of 5.2 months. Patients with locally advanced primary tumors or recurred in situ (n = 8) achieved 100% local control, and none of them got recurrence or distant metastasis after radiotherapy at last follow-up (median 29 months). Of patients with catecholamine-related syndromes (n = 12), 91% of symptomatic lesions improved following radiation therapy and a more than 50% decline in catecholamines. CONCLUSIONS: We have found hypofractionated IMRT effective as an additional therapy for patients with advanced primary tumors or recurrence in situ and not amenable to complete surgical resection.
PURPOSE: The purpose of this study was to review outcomes of patients with advanced/metastatic pheochromocytoma/paraganglioma (PPGL) treated at our institution with Intensity-modulated radiotherapy (IMRT), describe the treatment outcomes, and determine predictors. METHODS: A retrospective study on patients with advanced/metastatic PPGL who received IMRT at Peking Union Medical College Hospital between 2014 and 2019. A total of 14 patients with 17 lesions were included in this study. Ultra-hypofractionated radiation therapy was used for 7 lesions in 5 patients, while hypofractionated radiation therapy was used for 8 lesions in 7 patients. 2 patients got conventional fractionated radiotherapy. Patients who received external beam radiation therapy were given a median total radiation dose of 74.4/130 Gy (BED10/3) in a median of 13 fractions. RESULTS: OS at 2 years was 78% for all patients. For lesions evaluated by RECIST response, at least stable disease of the target lesion was achieved in 94% and distant progression in 28.5%, with an average time to progression of 5.2 months. Patients with locally advanced primary tumors or recurred in situ (n = 8) achieved 100% local control, and none of them got recurrence or distant metastasis after radiotherapy at last follow-up (median 29 months). Of patients with catecholamine-related syndromes (n = 12), 91% of symptomatic lesions improved following radiation therapy and a more than 50% decline in catecholamines. CONCLUSIONS: We have found hypofractionated IMRT effective as an additional therapy for patients with advanced primary tumors or recurrence in situ and not amenable to complete surgical resection.
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young Journal: J Clin Endocrinol Metab Date: 2014-06 Impact factor: 5.958
Authors: L Fishbein; L Bonner; D A Torigian; K L Nathanson; D L Cohen; D Pryma; K A Cengel Journal: Horm Metab Res Date: 2012-05-07 Impact factor: 2.936
Authors: Grainne M O'Kane; Shereen Ezzat; Anthony M Joshua; Isabelle Bourdeau; Raya Leibowitz-Amit; Harold J Olney; Monika Krzyzanowska; Dean Reuther; Soo Chin; Lisa Wang; Kelly Brooks; Aaron R Hansen; Sylvia L Asa; Jennifer J Knox Journal: Br J Cancer Date: 2019-05-20 Impact factor: 7.640
Authors: Jennifer Vogel; Aileen Sia Atanacio; Tamara Prodanov; Baris Ismail Turkbey; Karen Adams; Victoria Martucci; Kevin Camphausen; Antonio Tito Fojo; Karel Pacak; Aradhana Kaushal Journal: Front Oncol Date: 2014-06-27 Impact factor: 6.244
Authors: William Breen; Irina Bancos; William F Young; Keith C Bible; Nadia N Laack; Robert L Foote; Christopher L Hallemeier Journal: Adv Radiat Oncol Date: 2017-11-22
Authors: G De Filpo; G Cantini; G Rastrelli; G Vannini; T Ercolino; M Luconi; M Mannelli; M Maggi; L Canu Journal: J Endocrinol Invest Date: 2021-07-05 Impact factor: 4.256